Johnson & Johnson launched a new large-scale late-stage trial on Monday to test a two-dose regimen of its experimental COVID-19 vaccine and evaluate potential incremental benefits for the duration of protection with a second dose. The trial follows positive interim results from the company's ongoing early to mid stage clinical study that showed a single dose of its vaccine candidate induced a robust immune response and was generally well-tolerated. "The study will assess efficacy of the investigational vaccine after both the first and second dose to evaluate protection against the virus and potential incremental benefits for duration of protection with a second dose," J&J said in a statement. The platform, called AdVac, is also used in an Ebola vaccine that was approved earlier this year. Recruitment into the study will complete in March 2021 and the trial will last for 12 months.

Source: Mint November 16, 2020 05:26 UTC